iBio
IBIO
77 hedge funds and large institutions have $25M invested in iBio in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 24 increasing their positions, 22 reducing their positions, and 17 closing their positions.
9% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 22
0% more ownership
Funds ownership: 0.04% → 0.04% (+0%)
9% less funds holding
Funds holding: 85 → 77 (-8)
41% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 17
47% less call options, than puts
Call options by funds: $367K | Put options by funds: $690K
48% less capital invested
Capital invested by funds: $47.6M → $25M (-$22.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$185K |
| 2 |
AGM
Alpine Global Management
New York
|
+$172K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$166K |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$141K |
| 5 |
Barclays
London,
United Kingdom
|
+$133K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$251K |
| 2 |
Squarepoint
New York
|
-$202K |
| 3 |
Renaissance Technologies
New York
|
-$161K |
| 4 |
MIM
MetLife Investment Management
Whippany,
New Jersey
|
-$88.2K |
| 5 |
MLICM
Metropolitan Life Insurance Company (MetLife)
New York
|
-$66.7K |
IBIO Hedge Fund Activity: Q4 2021 in Review
77 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in iBio (IBIO) for Q4 2021, worth a combined $25M — down 48% from $47.6M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of IBIO and 10 opened new positions — a net loss of 7 holders — while 22 trimmed existing stakes and 24 added.
The largest buyer was Citadel Advisors, adding an estimated $185K. The largest seller was Geode Capital Management, cutting an estimated $251K.
- 77 institutional investors held iBio (IBIO) as of Q4 2021, down from 85 in Q3 2021.
- Funds reported $25M of iBio stock for Q4 2021, down 48% quarter-over-quarter.
- 10 funds opened new iBio positions in Q4 2021 and 17 closed out, a net change of -7 holders.
- The largest iBio buyer in Q4 2021 was Citadel Advisors, an estimated $185K added.
- The largest iBio seller in Q4 2021 was Geode Capital Management, an estimated $251K sold.
Based on aggregated 13F filings for Q4 2021.